Research Evonik Teams Up for mRNA Drug Transport Technology
Evonik has partnered with Stanford University to develop a mRNA drug transport technology which aims to deliver mRNA to different tissues and organs in the human body.
Essen/Germany – Specialty chemicals group Evonik is cooperating with the U.S. university Stanford in its search for new ways to transport mRNA-based drugs to the right places in the body. The goal of the three-year collaboration is to develop a technology that goes beyond the current possibilities of lipid nanoparticles, Evonik recently announced in Essen, Germany.
To this end, a polymer-based system will be developed, which the company will license and market. The aim is to expand the potential applications of mRNA therapeutics to better combat diseases such as cancer and Aids in the future.
If successful, Evonik would thus expand its product range based on mRNA transport technology and drive forward the portfolio restructuring of the Nutrition & Care division toward system solutions. The share of such system solutions in the division is expected to rise from 20 percent today to more than 50 percent by 2030.
Evonik already produces lipid nanoparticles (LNP) for the Corona vaccine from Biontech and Pfizer. Currently, Evonik's accessible market potential for LNP-based delivery systems is estimated to exceed 5 billion dollars by 2026, it added. However, competition in this area is also increasing.